Inogen Crecimiento futuro
Future controles de criterios 0/6
Se prevé un crecimiento anual de los beneficios y los ingresos de Inogen de 51.4% y 6.3% respectivamente, mientras que el BPA crecerá en un 36.6% al año.
Información clave
51.4%
Tasa de crecimiento de los beneficios
36.64%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Medical Equipment | 16.1% |
| Tasa de crecimiento de los ingresos | 6.3% |
| Rentabilidad financiera futura | n/a |
| Cobertura de analistas | Low |
| Última actualización | 15 May 2026 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
Actualización de narrativa • May 09
INGN: Bullish Initiation And Buyback Program Will Support Future Upside
Analysts have trimmed their price target on Inogen from about $13.00 to roughly $12.67, reflecting updated assumptions around revenue, profit margins and future P/E following fresh bullish initiation research from the Street. Analyst Commentary Analysts are using the fresh bullish initiation as a chance to refresh their models, focus on execution and reassess how much they are willing to pay for Inogen at the current P/E.
Actualización de narrativa • Apr 19
INGN: Buybacks And New Leadership Will Support Future Returns
Analysts have adjusted their price target on Inogen to $12.00, reflecting updated views on revenue growth assumptions, profit margin expectations, and the valuation multiple following recently published Street research, including a positive initiation of coverage. Analyst Commentary Recent Street research on Inogen has combined a constructive long term narrative with a more restrained tone on execution risks and how much investors are currently being asked to pay for that story.Actualización de narrativa • Apr 04
INGN: Sleep Therapy Expansion And Buybacks Will Support Future Returns
Analysts have adjusted their price target on Inogen to $12.00, reflecting updated assumptions around the discount rate, revenue growth, profit margin, and future P/E, which keep the fair value view broadly in line with prior estimates. What's in the News Inogen appointed Jason Richardson as Chief Financial Officer, effective April 6, 2026, succeeding Michael Bourque, who will remain in an advisory role until June 30, 2026 (Key Developments).Actualización de narrativa • Mar 21
INGN: Sleep Therapy Expansion And Buybacks Will Support Future Earnings Power
Analysts have maintained their price target for Inogen at $12.00, making small adjustments to assumptions around the discount rate, revenue growth, profit margin, and future P/E, which together result in an unchanged fair value view. What's in the News Inogen approved a share repurchase program of up to US$30 million of its common stock, funded by cash flow and existing cash reserves, with an expiry on the earlier of December 31, 2027, or when the full amount is used (Key Developments).Actualización de narrativa • Mar 06
INGN: Sleep Therapy Expansion And Buybacks Will Support Future Undervalued Upside
Analysts maintained their fair value estimate for Inogen at $13.00, citing slightly adjusted assumptions around the discount rate, revenue growth, profit margin, and future P/E that refine rather than significantly change their prior view. What's in the News Inogen announced a share repurchase program authorizing the company to buy back up to US$30 million of its common stock, funded by cash flow and existing cash reserves, with the program running until the earlier of December 31, 2027, or when the full amount is used (Key Developments).Actualización de narrativa • Feb 20
INGN: Sleep Therapy Portfolio Expansion Will Support Future Earnings Power
Analysts have adjusted their price target on Inogen to $12.00. The change reflects updated assumptions around discount rate, revenue growth, profit margin and future P/E expectations.Actualización de narrativa • Feb 06
INGN: Sleep Therapy Expansion Will Support Future Confidence In Undervalued Shares
Analysts have kept their price target for Inogen steady at US$13.00. This reflects only minor tweaks to assumptions for discount rate, revenue growth, profit margin, and future P/E that do not materially change their overall view of the stock.Actualización de narrativa • Jan 22
INGN: Sleep Therapy Expansion Will Support Future Earnings Power Ahead
Narrative Update on Inogen Analysts have modestly adjusted their price target on Inogen to reflect updated assumptions for discount rate, revenue growth, profit margin and future P/E. This has led to a refined valuation that still centers around a fair value of $12.00 per share.Actualización de narrativa • Jan 08
INGN: Stable Guidance And New Respiratory Line Will Support Future Confidence
Analysts have kept their price target for Inogen broadly in line with prior views, with only a small adjustment supported by updated assumptions around discount rate, profit margin and future P/E expectations, rather than any major shift in the outlook. What's in the News Inogen launched Aurora CPAP masks as a new product line within its respiratory care portfolio, targeting patients with obstructive sleep apnea through the F1 Full Face, N1 Nasal Cushion, and P1 Nasal Pillows range (Key Developments).Actualización de narrativa • Dec 16
INGN: Rising Revenue Outlook Will Support Stronger Earnings Power Ahead
Analysts have raised their price target on Inogen by approximately $5 to around $12 per share, reflecting modestly higher expectations for revenue growth, profit margins, and future earnings multiples, despite a slightly higher assumed discount rate. What's in the News Issued new fourth quarter 2025 revenue guidance of $87 million to $90 million, implying roughly 10% year over year growth at the midpoint compared to fourth quarter 2024 (company guidance) Reiterated full year 2025 revenue outlook of $354 million to $357 million, targeting about 6% growth at the midpoint versus 2024 revenue (company guidance) Emphasized that the updated outlook reflects confidence in execution while maintaining a disciplined view of demand and pricing conditions in the portable oxygen concentrator market (company guidance) Valuation Changes The fair value estimate has risen materially, increasing from approximately $7.00 to $12.00 per share.Actualización de narrativa • Dec 02
INGN: Guidance Stability Will Drive Confidence As Margins Poised To Improve
Analysts have maintained their price target for Inogen at $13.00. This reflects minimal changes in financial assumptions and a steady outlook for the company's revenue growth and profitability.Actualización de narrativa • Nov 18
INGN: Profit Margins Will Strengthen As Revenue Guidance Remains Encouraging
Analysts have adjusted Inogen’s price target to $13.00. This is a slight change that reflects expectations of improved profit margins, despite modest revisions in growth rates and valuation metrics.Seeking Alpha • Nov 11
Slow Progress At Inogen ... But Progress All The Same
Summary Inogen (INGN) continues its turnaround, showing progress in revenue growth and margins, but the pace remains slower and riskier than the market desires. INGN posted positive adjusted EBITDA and raised full-year guidance, despite mixed quarterly results and ongoing volatility in direct-to-consumer and rental segments. The company’s strong market position, new product launches, and partnerships offer long-term growth potential, especially as patients consistently prefer portable solutions. Valuation appears deeply discounted, with net cash and little credit for progress; INGN offers speculative upside for risk-tolerant investors if improvements persist. Read the full article on Seeking AlphaActualización de narrativa • Nov 03
INGN: Profit Margins Will Strengthen Amid Broader Respiratory Care Market Expansion
Analysts have slightly increased their price target for Inogen to $13.00 per share. This change reflects modest adjustments to profit margin forecasts and discount rates in their updated models.Actualización de narrativa • Oct 20
Home And Outpatient Respiratory Care Will Expand Market Opportunities
Analysts have reaffirmed their price target for Inogen at $13.00, citing stable outlooks with only minor adjustments to key financial metrics. What's in the News Inogen issued new earnings guidance for the third quarter of 2025, projecting revenue between $91 million and $93 million.Actualización de narrativa • Oct 05
Home And Outpatient Respiratory Care Will Expand Market Opportunities
Analysts have raised their price target for Inogen from $11.00 to $13.00, citing updated projections of slightly stronger revenue growth and reduced discount rates as key contributors to the increased valuation. What's in the News Inogen, Inc.Artículo de análisis • Aug 31
There's No Escaping Inogen, Inc.'s (NASDAQ:INGN) Muted Revenues Despite A 29% Share Price Rise
The Inogen, Inc. ( NASDAQ:INGN ) share price has done very well over the last month, posting an excellent gain of 29...Actualización de narrativa • Aug 10
Home And Outpatient Respiratory Care Will Expand Market Opportunities
Despite an upward revision in revenue growth forecasts and a lower future P/E, the analyst consensus price target for Inogen has decreased from $11.67 to $11.00, indicating increased caution around the company’s fair value. What's in the News Inogen expects third quarter 2025 revenue of $91–93 million (~4% YoY growth) and full-year 2025 revenue of $354–357 million (~6% YoY growth).Artículo de análisis • May 10
Analysts Have Been Trimming Their Inogen, Inc. (NASDAQ:INGN) Price Target After Its Latest Report
A week ago, Inogen, Inc. ( NASDAQ:INGN ) came out with a strong set of quarterly numbers that could potentially lead to...
Nueva narrativa • Apr 01
Yuwell Collaboration Will Open Chinese Respiratory Market
Strategic partnerships and product innovation in China and digital health are expected to drive growth and improve earnings potential.Artículo de análisis • Mar 08
Why Investors Shouldn't Be Surprised By Inogen, Inc.'s (NASDAQ:INGN) 35% Share Price Plunge
Inogen, Inc. ( NASDAQ:INGN ) shareholders won't be pleased to see that the share price has had a very rough month...Seeking Alpha • Mar 01
A Volatile Share Price Masks Some Of The Progress At Inogen
Summary Inogen's new management and strategy are yielding results, with better-than-expected 2024 performance and a more stable base from which to keep growing the B2B business. Despite weak DTC sales, strong B2B growth drove better-than-expected sales in Q4, and Inogen likewise beat on margins. Guidance disappointed investors and prompted a 15% drop in the shares, as moderately better revenue guidance was offset by unexpected gross margin deleverage. Key recent developments include FDA approval of the Simeox device and a strategic partnership with Yuwell, both offering long-term growth potential but requiring time to ramp. While 2024 progress is promising and the valuation is not at all demanding, significant risks remain, particularly in revenue acceleration and margin leverage, making Inogen a high-risk but intriguing speculative investment. Read the full article on Seeking AlphaArtículo de análisis • Feb 28
Inogen, Inc. (NASDAQ:INGN) Released Earnings Last Week And Analysts Lifted Their Price Target To US$10.00
Shareholders in Inogen, Inc. ( NASDAQ:INGN ) had a terrible week, as shares crashed 23% to US$7.95 in the week since...Artículo de análisis • Jan 22
Inogen, Inc. (NASDAQ:INGN) Held Back By Insufficient Growth Even After Shares Climb 32%
Inogen, Inc. ( NASDAQ:INGN ) shareholders would be excited to see that the share price has had a great month, posting a...Seeking Alpha • Sep 24
Inogen: Upside Seems Limited After Big Move Up
Summary Inogen, Inc. manufactures portable oxygen concentrators and related accessories. The shares have doubled over the past year, but the equity is still trading at roughly 75% of annual sales. Despite an earnings beat in Q2, Wall Street analysts are cautious about the stock's current prospects. Inogen boasts a strong balance sheet with over $120 million in cash (which is roughly half the stock's market cap) and no long-term debt. An analysis of Inogen follows in the paragraphs below. Read the full article on Seeking AlphaArtículo de análisis • Jul 16
Inogen, Inc.'s (NASDAQ:INGN) Price Is Right But Growth Is Lacking After Shares Rocket 26%
Despite an already strong run, Inogen, Inc. ( NASDAQ:INGN ) shares have been powering on, with a gain of 26% in the...Seeking Alpha • Jul 01
Inogen: Improving, But Still Struggling For Air
Summary Inogen aims to help millions suffering from COPD with portable oxygen delivery machines, but its financial performance has been inconsistent. Inogen faced execution issues, but recent improvements in operating momentum due to competitor exits and new management team are sparking optimism. Recent revenue growth, cost cuts, and narrowing losses are encouraging, but shares remain highly speculative and further progress is needed for a more positive outlook. Read the full article on Seeking AlphaArtículo de análisis • May 22
Inogen, Inc. (NASDAQ:INGN) Stock Catapults 28% Though Its Price And Business Still Lag The Industry
Inogen, Inc. ( NASDAQ:INGN ) shareholders are no doubt pleased to see that the share price has bounced 28% in the last...Seeking Alpha • Apr 13
Inogen: New Management And A Major Competitor Exit Offer Some New Opportunities
Summary Inogen has continued to struggle, with growth in the rental business overshadowed by declines in direct-to-consumer sales, volatility in business-to-business sales, and pricing pressures. Inogen has the opportunity to leverage the exit of a major competitor, Philips, from the portable oxygen concentrator (POC) market. The new management team aims to position Inogen as the premium POC provider and partner with home medical equipment companies, while also focusing on the Physio-Assist opportunity. Inogen shares trade at a steep discount, but the Street typically wants nothing to do with low-growth small-cap med-tech, so management must present a credible plan for meaningful sustained growth. Read the full article on Seeking AlphaArtículo de análisis • Mar 01
Inogen, Inc. (NASDAQ:INGN) Just Reported, And Analysts Assigned A US$6.50 Price Target
There's been a major selloff in Inogen, Inc. ( NASDAQ:INGN ) shares in the week since it released its annual report...Artículo de análisis • Feb 01
Inogen, Inc. (NASDAQ:INGN) Held Back By Insufficient Growth Even After Shares Climb 25%
Despite an already strong run, Inogen, Inc. ( NASDAQ:INGN ) shares have been powering on, with a gain of 25% in the...Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 12/31/2028 | 417 | -10 | 0 | 19 | 2 |
| 12/31/2027 | 397 | -13 | 1 | 18 | 3 |
| 12/31/2026 | 369 | -22 | -5 | 9 | 3 |
| 3/31/2026 | 351 | -25 | -10 | -1 | N/A |
| 12/31/2025 | 349 | -23 | -22 | -11 | N/A |
| 9/30/2025 | 347 | -25 | -24 | -13 | N/A |
| 6/30/2025 | 343 | -26 | -22 | -8 | N/A |
| 3/31/2025 | 340 | -27 | -21 | -6 | N/A |
| 12/31/2024 | 336 | -36 | -11 | 6 | N/A |
| 9/30/2024 | 332 | -53 | -14 | 6 | N/A |
| 6/30/2024 | 327 | -92 | -20 | 1 | N/A |
| 3/31/2024 | 322 | -97 | -26 | -2 | N/A |
| 12/31/2023 | 316 | -102 | -30 | -3 | N/A |
| 9/30/2023 | 328 | -133 | -43 | -16 | N/A |
| 6/30/2023 | 349 | -96 | -55 | -27 | N/A |
| 3/31/2023 | 369 | -90 | -50 | -26 | N/A |
| 12/31/2022 | 377 | -84 | -59 | -38 | N/A |
| 9/30/2022 | 366 | -50 | -36 | -16 | N/A |
| 6/30/2022 | 353 | -28 | -31 | -9 | N/A |
| 3/31/2022 | 351 | -20 | -20 | 3 | N/A |
| 12/31/2021 | 358 | -6 | 0 | 24 | N/A |
| 9/30/2021 | 356 | 11 | 9 | 33 | N/A |
| 6/30/2021 | 337 | -2 | 20 | 43 | N/A |
| 3/31/2021 | 307 | -5 | 19 | 39 | N/A |
| 12/31/2020 | 308 | -6 | 19 | 37 | N/A |
| 9/30/2020 | 313 | -2 | 16 | 30 | N/A |
| 6/30/2020 | 331 | 6 | 29 | 38 | N/A |
| 3/31/2020 | 360 | 14 | 36 | 43 | N/A |
| 12/31/2019 | 362 | 21 | N/A | 41 | N/A |
| 9/30/2019 | 370 | 32 | N/A | 44 | N/A |
| 6/30/2019 | 373 | 42 | N/A | 43 | N/A |
| 3/31/2019 | 369 | 46 | N/A | 46 | N/A |
| 12/31/2018 | 358 | 52 | N/A | 60 | N/A |
| 9/30/2018 | 335 | 41 | N/A | 61 | N/A |
| 6/30/2018 | 309 | 32 | N/A | 64 | N/A |
| 3/31/2018 | 276 | 26 | N/A | 60 | N/A |
| 12/31/2017 | 249 | 21 | N/A | 60 | N/A |
| 9/30/2017 | 237 | 27 | N/A | 53 | N/A |
| 6/30/2017 | 222 | 25 | N/A | 44 | N/A |
| 3/31/2017 | 212 | 24 | N/A | 39 | N/A |
| 12/31/2016 | 203 | 21 | N/A | 31 | N/A |
| 9/30/2016 | 192 | 19 | N/A | 38 | N/A |
| 6/30/2016 | 179 | 17 | N/A | 41 | N/A |
| 3/31/2016 | 168 | 13 | N/A | 37 | N/A |
| 12/31/2015 | 159 | 12 | N/A | 38 | N/A |
| 9/30/2015 | 148 | 9 | N/A | 30 | N/A |
| 6/30/2015 | 136 | 9 | N/A | 21 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: Se prevé que INGN siga sin ser rentable en los próximos 3 años.
Beneficios vs. Mercado: Se prevé que INGN siga sin ser rentable en los próximos 3 años.
Beneficios de alto crecimiento: Se prevé que INGN siga sin ser rentable en los próximos 3 años.
Ingresos vs. Mercado: Se prevé que los ingresos (6.3% al año) de INGN crezcan más despacio que el mercado de US (11.6% al año).
Ingresos de alto crecimiento: Se prevé que los ingresos 6.3% al año) de INGN crezcan más despacio que 20% al año.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de INGN se prevé que sea elevada dentro de 3 años.
Descubre empresas en crecimiento
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/20 14:40 |
| Precio de las acciones al final del día | 2026/05/20 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Inogen, Inc. está cubierta por 9 analistas. 3 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Anderson Schock | B. Riley Securities, Inc. |
| Ilya Zubkov | Freedom Broker |
| Matthew Mishan | KeyBanc Capital Markets Inc. |